Actively Recruiting
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2025-04-22
20
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.
CONDITIONS
Official Title
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Volunteer for the trial with signed informed consent by the patient or legal guardian
- Age between 18 and 75 years old, any gender
- Tumor lesions detected by other imaging methods such as CT or MRI
- Diagnosed with lung cancer, thyroid cancer, pancreatic cancer, melanoma, or neuroendocrine tumors with final pathological results available
- Kidney function with GFR > 50 ml/min, ERPF > 280 ml/min
- Platelet count > 75,000/μL, white blood cell count > 3,000/μL
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 3 times the normal value
You will not qualify if you...
- History of allergy to drugs similar to FAPI, allergic constitution, or current allergic diseases
- Currently or previously participating in other clinical drug research (excluding vitamins and minerals)
- Uncontrolled serious clinical problems such as HIV, hepatitis B or C, serious infections, or severe mental, neurological, cardiovascular, respiratory diseases
- Red blood cell count < 4 × 10^12, white blood cell count < 3 × 10^9, hemoglobin < 110 g/L, platelet count < 75,000 × 10^9
- Significant liver or kidney dysfunction with GFR less than 50 ml/min
- Tumor burden over 50% or significant spinal cord compression
- Expected survival less than six months
- Recent chemotherapy within six months
- Severe acute illnesses or refractory mental disorders
- Pregnant or breastfeeding women
- Physical condition unsuitable for radiation examination
- Other conditions deemed unsuitable by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanjing First Hospital
Nanjing, Jiangsu, China, 210001
Actively Recruiting
Research Team
F
Feng Wang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here